Thanatsaran Saenlom

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Induced Pluripotent Stem Cells

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Kodchakorn Mahasongkram, Kantaphon Glab-Ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang, Wanpen Chaicumpa
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer. Vaccines 11 (12) (2023)
Kanasap Kaewchim, Kantaphon Glab-Ampai, Kodchakorn Mahasongkram, Thanatsaran Saenlom, Watayagorn Thepsawat, Monrat Chulanetra, Kiattawee Choowongkomon, Nitat Sookrung, Wanpen Chaicumpa
Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 15 (6) (2023)
Kanasap Kaewchim, Kantaphon Glab-Ampai, Kodchakorn Mahasongkram, Thanatsaran Saenlom, Watayagorn Thepsawat, Monrat Chulanetra, Kiattawee Choowongkomon, Nitat Sookrung, Wanpen Chaicumpa
Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 15 (6) (2023)
Kanasap Kaewchim, Kantaphon Glab-Ampai, Kodchakorn Mahasongkram, Thanatsaran Saenlom, Watayagorn Thepsawat, Monrat Chulanetra, Kiattawee Choowongkomon, Nitat Sookrung, Wanpen Chaicumpa
Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 15 (6) (2023)
Kanasap Kaewchim, Kantaphon Glab-Ampai, Kodchakorn Mahasongkram, Thanatsaran Saenlom, Watayagorn Thepsawat, Monrat Chulanetra, Kiattawee Choowongkomon, Nitat Sookrung, Wanpen Chaicumpa
Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15 , 1252. Viruses 15 (10) (2023)
Kodchakorn Mahasongkram, Kantaphon Glab-Ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang, Wanpen Chaicumpa
Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer. Vaccines 11 (12) (2023)